The cholera toxin B subunit is a mucosal adjuvant for oral tolerance induction in type 1 diabetes

被引:26
作者
Bregenholt, S
Wang, M
Wolfe, T
Hughes, A
Bærentzen, L
Dyrberg, T
von Herrath, MG
Petersen, JS
机构
[1] Novo Nordisk AS, Islet Discovery Res, DK-2880 Bagsvaerd, Denmark
[2] La Jolla Inst Allergy & Immunol, San Diego, CA USA
[3] Novo Nordisk AS, Clin Drug Dev, DK-2880 Bagsvaerd, Denmark
关键词
D O I
10.1046/j.1365-3083.2003.01248.x
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
When conjugated to various proteins, the nontoxic B-chain of cholera toxin (CTB) significantly increases the ability of these proteins to induce immunological tolerance after oral administration. Here, we investigated if a nonconjugated form of CTB enhances the induction of immune tolerance after oral insulin administration. Induction of immunological tolerance was studied after oral administration of insulin preparations in three mouse models; an insulin/ovalbumin coimmunization model, a model of virus-induced diabetes in transgenic RIP-LCMV-NP mice and in nonobese diabetic (NOD) mice serving as a model of spontaneous diabetes. In the immunization model, we demonstrate that mixing with CTB increases the tolerogenic potential of insulin, approximately 10 fold. Titration of the CTB concentration in this system revealed that an insulin : CTB ratio of 100 : 1 was optimal for the induction of bystander suppression. Further studies revealed that this insulin : CTB ratio also was optimal for the prevention of diabetes in a virus-induced, transgenic diabetes model. In addition, the administration of this optimal insulin-CTB preparation significantly prevented the onset of diabetes in old NOD mice with established islet infiltration. The data presented here demonstrate that CTB, even in its unconjugated form, functions as a mucosal adjuvant, increasing the specific tolerogenic effect of oral insulin.
引用
收藏
页码:432 / 438
页数:7
相关论文
共 42 条
[1]   Insulin B-chain reactive CD4+ regulatory T-cells induced by oral insulin treatment protect from type 1 diabetes by blocking the cytokine secretion and pancreatic infiltration of diabetogenic effector T-cells [J].
Bergerot, I ;
Arreaza, GA ;
Cameron, MJ ;
Burdick, MD ;
Strieter, RM ;
Chensue, SW ;
Chakrabarti, S ;
Delovitch, TL .
DIABETES, 1999, 48 (09) :1720-1729
[2]   A cholera toxoid-insulin conjugate as an oral vaccine against spontaneous autoimmune diabetes [J].
Bergerot, I ;
Ploix, C ;
Petersen, J ;
Moulin, V ;
Rask, C ;
Fabien, N ;
Lindblad, M ;
Mayer, A ;
Czerkinsky, C ;
Holmgren, J ;
Thivolet, C .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (09) :4610-4614
[3]   Oral administration of recombinant cholera toxin subunit B inhibits IL-12-mediated murine experimental (trinitrobenzene sulfonic acid) colitis [J].
Boirivant, M ;
Fuss, IJ ;
Ferroni, L ;
De Pascale, M ;
Strober, W .
JOURNAL OF IMMUNOLOGY, 2001, 166 (05) :3522-3532
[4]  
Bregenholt S, 1996, J IMMUNOL, V157, P993
[5]  
Bregenholt S, 2002, ANN NY ACAD SCI, V958, P179
[6]   Induction of tolerance in macrophages by cholera toxin B chain [J].
Burkart, V ;
Kim, YE ;
Kauer, M ;
Kolb, H .
PATHOBIOLOGY, 1999, 67 (5-6) :314-317
[7]   Oral insulin administration and residual β-cell function in recent-onset type 1 diabetes:: a multicentre randomised controlled trial [J].
Chaillous, L ;
Lefèvre, H ;
Thivolet, C ;
Boitard, C ;
Lahlou, N ;
Atlan-Gepner, C ;
Bouhanick, B ;
Mogenet, A ;
Nicolino, M ;
Carel, JC ;
Lecomte, P ;
Maréchaud, R ;
Bougnères, P ;
Charbonnel, B ;
Saï, P .
LANCET, 2000, 356 (9229) :545-549
[8]   Restoration of self-tolerance is a feasible approach to control ongoing beta-cell specific autoreactivity: its relevance for treatment in established diabetes and islet transplantation [J].
Chatenoud, L .
DIABETOLOGIA, 2001, 44 (05) :521-536
[9]  
FRANCIS ML, 1992, J IMMUNOL, V148, P1999
[10]   Oral tolerance in disease [J].
Garside, P ;
Mowat, AM ;
Khoruts, A .
GUT, 1999, 44 (01) :137-142